Ginkgo is a synthetic biology platform company based in Boston. We have established partnerships with Roche, Biogen, Moderna, Aldevron, Synlogic, and other major pharma/biotech companies. Ginkgo is not a CRO, but rather we partner with companies to make Biology Easier to Engineer, from Discovery through Manufacturing. Ginkgo leverages its platform to address the needs of over 40 Partners across 75+ products via high throughput automation, AI/ML, massive library construction, and multiple design/build/test cycles. With a state of the art, 260,000+ square foot facility, Ginkgo has successfully helped its partners to develop or improve production of a protein, small molecule, enzyme, or strain/cell line, among other applications. We work across a large number of microbial and mammalian hosts through our collaborations.
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance both basic research and therapeutic development programs. With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation enabling the next generation of medicines by delivering genome editing at an unprecedented scale.